Regulatory Context for Cardiology

Cardiology practice in the United States sits at the intersection of federal agency oversight, professional board standards, device and drug approval pathways, and state-level licensure law. Understanding this layered structure matters because gaps between authorities create compliance obligations that fall directly on cardiologists, hospitals, and cardiac device manufacturers. This page maps the primary regulatory bodies, identifies where exemptions apply, and traces how the framework has evolved around key clinical and technological developments.

Governing sources of authority

Cardiology regulation draws from at least four distinct institutional sources, each with independent enforcement power.

The Food and Drug Administration (FDA) controls approval and post-market surveillance of cardiac devices — including pacemakers, implantable cardioverter-defibrillators (ICDs), stents, and transcatheter heart valves — under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Chapter 9). High-risk cardiac devices classified as Class III require Premarket Approval (PMA), the most stringent FDA pathway, before commercial distribution. The FDA's Center for Devices and Radiological Health (CDRH) manages these submissions.

The Centers for Medicare & Medicaid Services (CMS) governs reimbursement eligibility and coverage determinations for cardiac procedures. National Coverage Determinations (NCDs) — such as those governing implantable cardioverter-defibrillators — set clinical criteria that directly shape which patients qualify for a covered procedure. CMS also administers the Physician Quality Reporting System and value-based care programs that impose cardiology-specific performance measures.

The American Board of Internal Medicine (ABIM) and its subspecialty certifications establish competency thresholds for practicing cardiologists. Board certification in cardiovascular disease, interventional cardiology, and clinical cardiac electrophysiology is governed by ABIM examination and maintenance-of-certification standards. While ABIM certification is technically voluntary at the federal level, hospital credentialing bodies and payers routinely require it as a condition of practice privileges. For a detailed breakdown of certification pathways, see Cardiology Board Certification.

State medical boards hold licensure authority under state police powers and set the legal floor for practice within each jurisdiction. Requirements vary across all 50 states for continuing medical education (CME) hours, scope of practice boundaries, and telemedicine cardiology delivery.

The following framework illustrates the four primary layers of cardiology regulation:

  1. Federal product approval — FDA Class III PMA for cardiac devices; FDA New Drug Application (NDA) for cardiac pharmaceuticals
  2. Federal coverage policy — CMS NCDs and Local Coverage Determinations (LCDs) governing procedural reimbursement
  3. Professional certification — ABIM board certification and fellowship accreditation through ACGME
  4. State licensure — State medical board requirements, including CME mandates ranging from 20 to 50 hours per renewal cycle depending on jurisdiction

Exemptions and carve-outs

The FDA's Humanitarian Device Exemption (HDE) pathway creates a significant carve-out for cardiac devices intended to treat or diagnose diseases affecting fewer than 8,000 individuals in the United States annually (FDA HDE Program, 21 CFR Part 814). Devices approved under HDE — including certain pediatric cardiac applications — are not required to demonstrate probable benefit in the same manner as a full PMA submission, though safety standards still apply.

For cardiac drugs, the Orphan Drug Act (21 U.S.C. § 360bb) provides extended market exclusivity and reduced regulatory fees for therapies targeting rare cardiac conditions such as transthyretin amyloid cardiomyopathy. This exclusivity period runs 7 years from approval, compared to the standard 5-year data exclusivity for non-biological drugs.

CMS also maintains specific coverage limitations that function as carve-outs in reverse — restricting coverage rather than expanding it. The ICD NCD, for example, excludes coverage when implantation is performed within 40 days of a myocardial infarction or within 3 months of coronary artery bypass grafting for primary prevention indications, based on clinical evidence reviewed during the NCD process.

The broader safety context and risk boundaries for cardiology intersects with these exemption structures, particularly where device approvals carry post-market study requirements as conditions of approval.

Where gaps in authority exist

Regulatory authority in cardiology is not seamless. Three structural gaps are consistently identified in policy literature.

Off-label device and drug use represents the largest gap. Once the FDA approves a cardiac device or drug, clinicians may use it outside approved indications. The FDA does not regulate the practice of medicine, so off-label use of cardiac stents or antiarrhythmic agents occurs without a corresponding federal approval mechanism, though it may affect CMS reimbursement eligibility.

Cardiac digital health and software falls into a contested regulatory zone. The FDA's Digital Health Center of Excellence has published guidance distinguishing Software as a Medical Device (SaMD) from lower-risk clinical decision support tools, but enforcement boundaries for AI-assisted cardiac imaging interpretation remained under active guidance development as of 2023 (FDA Digital Health Policy).

Interstate telemedicine cardiology exposes a jurisdictional gap between state licensure requirements. A cardiologist licensed in one state interpreting a remote electrocardiogram for a patient in another state may trigger licensure obligations in the patient's state. The Interstate Medical Licensure Compact (IMLC), active in 39 states and territories as of 2024, partially addresses this but does not cover all states (IMLC website).

How the regulatory landscape has shifted

Three developments have materially reshaped cardiology's regulatory environment over the past two decades.

The Medical Device User Fee Amendments (MDUFA), first enacted in 2002 and reauthorized in cycles under the FDA Reauthorization Act, introduced performance goals and review timelines for cardiac device applications, accelerating PMA review windows for high-priority cardiovascular devices.

The Affordable Care Act of 2010 expanded value-based purchasing programs administered by CMS, embedding cardiology-specific quality metrics into hospital payment rates. Conditions like acute myocardial infarction and heart failure became anchor diagnoses for the Hospital Value-Based Purchasing Program and Hospital Readmissions Reduction Program, creating financial incentives tied directly to cardiology outcomes data.

The 21st Century Cures Act of 2016 (Public Law 114-255) accelerated the Breakthrough Device Program, creating a dedicated pathway for cardiac technologies demonstrating potential to address unmet clinical needs. Transcatheter valve technologies and leadless pacing systems have moved through this pathway. The Act also addressed interoperability for cardiac electronic health records, with ONC implementation rules affecting how cardiology data is exchanged between institutions.

A full orientation to cardiology practice structure, including subspecialty divisions, is available at the site index.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)